Product Portfolio Expansion - The company has launched a new portfolio of designer proteins engineered using advanced AI-based design platforms and protein evolutionary workflows [4] - The expanded portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable, and Wnt/RSPO1, Wnt/RSPO2, and Wnt/RSPO3 Agonist proteins [4] - These proteins are designed to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion [2] Technological Innovation - The company leverages generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design [2] - The new proteins feature tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability [2] - The FGF basic Heat Stable protein is available in both RUO and GMP formats to support cell therapy manufacturing and advanced research [3] Market Leadership - The company continues to lead in delivering disruptive innovations to the life sciences and therapeutic development communities [5] - The designer proteins are part of the company's market-leading R&D Systems branded portfolio of proteins [5] Company Overview - The company is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities [6] - It generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide [6]

ST. PAUL, Minn., Jan. 8, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, today announced that Seattle Children's Therapeutics, a division of the Seattle Children's Research Institute has been awarded a $125,000 G-Rex Grant.  The G-Rex Grant will integrate state-of-the-art advancements into Seattle Children's Therapeutics' G-Rex based CAR-T cell platform. "This technology has been a core component of our CAR-T platform for many years, and we have m ...

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.   B ...

Company Overview - Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities [2] - The company's products assist in scientific investigations into biological processes, disease progression, drug discovery, and accurate clinical tests and diagnoses [2] - Bio-Techne has a portfolio of hundreds of thousands of products and generated approximately $1.2 billion in net sales in fiscal 2024 [2] - The company employs approximately 3,100 people worldwide [2] Upcoming Event - Kim Kelderman, President and CEO of Bio-Techne, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 10:30 a.m. PST [1] - A live webcast of the presentation will be available on Bio-Techne's Investor Relations website [1]

Guangzhou, Dec. 19, 2024 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 Class A ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per share for total gross proceeds of approximately $5,000,00 ...

MINNEAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS S ...

ST. PAUL, Minn., Dec. 18, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell therapy for the treatment of solid tumors."We are grateful to receive a G-Rex Grant to support the advancement of our lead CAR T asset into the clinic in a platform that ...

Bio-Techne Corp. (TECH) has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer.The research-use-only assay, which includes a qPCR detection kit and an isolation kit for cell-free DNA and exosomal RNA, will also be featured at the ongoing San Antonio Breast Cancer Symposium. The latest development is expected to bolster the company’s Diagnostics and Spatial Biology segmen ...

Core Insights - Bio-Techne (TECH) is advancing in its four growth verticals, which are expected to drive growth in upcoming quarters [1] - The company has achieved ISO 13485 certification and is now pursuing clinical diagnostic opportunities on the Ella platform [1][6] - Acquisitions remain a key strategy for Bio-Techne to expand its portfolio and enter adjacent markets, despite facing macroeconomic challenges and competitive pressures [1][7][10] Growth Verticals - The Proteomics Analytical Instrumentation franchise, under the ProteinSimple brand, reported mid-single-digit growth in fiscal 2024, driven by SimplePlex and SimpleWestern products [4] - The Cell and Gene Therapy vertical is experiencing growth due to strong biotech funding and customer additions [4] - The Diagnostics and Spatial Biology vertical is showing solid growth, with positive responses from newly added RNAscope assays [5] - The Molecular Diagnostics vertical achieved nearly 40% growth in the first quarter of fiscal 2025, particularly in the ExoDx prostate test and Asuragen kit business [5] Ella Platform and Strategic Acquisitions - The Ella platform, following ISO 13485 certification, is gaining traction in clinical diagnostics, particularly for cell and gene therapy applications [6] - Bio-Techne's acquisition of Lunaphore is aimed at scaling up instrument production capacity to meet demand [7] - The company has made a 19.9% investment in Wilson Wolf and plans to acquire the remaining ownership by the end of calendar year 2027 [8] Challenges - The macroeconomic environment, especially in Asia Pacific and Europe, is leading to increased raw material and labor costs, which may impact operations through 2024 [10] - Bio-Techne faces intense competition from both large global companies and smaller niche players, leading to pricing pressures [11] Financial Performance - Over the past year, Bio-Techne's shares have increased by 15.4%, outperforming the industry growth of 0.9% [2] - The company's market capitalization stands at $11.97 billion, with fiscal 2025 earnings estimates recently adjusted down by 6 cents to $1.92 [2][12] - Revenue estimates for fiscal 2025 are projected at $1.22 billion, indicating a 5.6% increase from the previous year [12]

WEST SACRAMENTO, Calif., Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH).GeminiBio has a 39-year history of supporting FBS customers. With this agreement, GeminiBio builds ...